Ad is loading...
LSTA
Price
$2.81
Change
+$0.02 (+0.72%)
Updated
Nov 14 closing price
132 days until earnings call
MDGL
Price
$302.67
Change
-$12.48 (-3.96%)
Updated
Nov 14 closing price
103 days until earnings call
Ad is loading...

LSTA vs MDGL

Header iconLSTA vs MDGL Comparison
Open Charts LSTA vs MDGLBanner chart's image
Lisata Therapeutics
Price$2.81
Change+$0.02 (+0.72%)
Volume$3.98K
CapitalizationN/A
Madrigal Pharmaceuticals
Price$302.67
Change-$12.48 (-3.96%)
Volume$405.26K
CapitalizationN/A
LSTA vs MDGL Comparison Chart
Loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
LSTA vs. MDGL commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSTA is a StrongSell and MDGL is a Sell.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (LSTA: $2.81 vs. MDGL: $302.67)
Brand notoriety: LSTA and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSTA: 31% vs. MDGL: 99%
Market capitalization -- LSTA: $23.38M vs. MDGL: $6.6B
LSTA [@Biotechnology] is valued at $23.38M. MDGL’s [@Biotechnology] market capitalization is $6.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSTA’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • LSTA’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than LSTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSTA’s TA Score shows that 2 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • LSTA’s TA Score: 2 bullish, 7 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than LSTA.

Price Growth

LSTA (@Biotechnology) experienced а -3.44% price change this week, while MDGL (@Biotechnology) price change was -14.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +6.14%.

Reported Earning Dates

LSTA is expected to report earnings on Mar 27, 2025.

MDGL is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.6B) has a higher market cap than LSTA($23.4M). MDGL YTD gains are higher at: 30.811 vs. LSTA (2.930). LSTA has higher annual earnings (EBITDA): -23.93M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. LSTA (38.3M). LSTA has less debt than MDGL: LSTA (176K) vs MDGL (119M). MDGL has higher revenues than LSTA: MDGL (76.8M) vs LSTA (0).
LSTAMDGLLSTA / MDGL
Capitalization23.4M6.6B0%
EBITDA-23.93M-502.65M5%
Gain YTD2.93030.81110%
P/E RatioN/AN/A-
Revenue076.8M-
Total Cash38.3M999M4%
Total Debt176K119M0%
FUNDAMENTALS RATINGS
LSTA vs MDGL: Fundamental Ratings
LSTA
MDGL
OUTLOOK RATING
1..100
6724
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
10030
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
5536
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (15) in the null industry is somewhat better than the same rating for MDGL (69) in the Pharmaceuticals Other industry. This means that LSTA’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is significantly better than the same rating for LSTA (100) in the null industry. This means that MDGL’s stock grew significantly faster than LSTA’s over the last 12 months.

LSTA's SMR Rating (95) in the null industry is in the same range as MDGL (97) in the Pharmaceuticals Other industry. This means that LSTA’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as LSTA (55) in the null industry. This means that MDGL’s stock grew similarly to LSTA’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as LSTA (100) in the null industry. This means that MDGL’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LSTAMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MBBB21.41N/A
N/A
VanEck Mdy's Aly BBB Corp Bd ETF
XCOR71.57N/A
N/A
FundX ETF
PJUN37.44-0.06
-0.16%
Innovator U.S. Equity Power BffrETF™-Jun
MAYW30.42-0.05
-0.16%
AllianzIM U.S. Large Cp Buffer20 May ETF
CGGO29.75-0.14
-0.47%
Capital Group Global Growth Equity ETF

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and ARWR have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and ARWR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+0.72%
ARWR - LSTA
26%
Poorly correlated
-1.02%
ASND - LSTA
26%
Poorly correlated
-1.39%
MRUS - LSTA
25%
Poorly correlated
-2.49%
AMLX - LSTA
25%
Poorly correlated
-11.62%
MDGL - LSTA
24%
Poorly correlated
-3.96%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with VXRT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then VXRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-3.96%
VXRT - MDGL
61%
Loosely correlated
-11.80%
ALXO - MDGL
56%
Loosely correlated
-0.75%
REPL - MDGL
55%
Loosely correlated
-2.48%
ZNTL - MDGL
51%
Loosely correlated
+0.77%
CGEM - MDGL
50%
Loosely correlated
-3.10%
More